TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05828459
Drug: IMids
Normalized name: N-Phthalylglutamic acid imide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle
Study: NCT05828459
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination regimen for solid tumor Bevacizumab: 10 mg/m² q2w
Study: NCT05828459
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination regimen for solid tumor Paclitaxel: 175 mg/m² q3w
Study: NCT05828459
Drug: TBD Compound
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination regimen for hematological malignancy
Study: NCT06464510
Drug: Early Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Vasopressin group: Vasopressin up to 0.04U/min initiated after randomization.
Study: NCT06464510
Drug: Norepinephrine and Vasopressin for Rescue
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine and Vasopressin for Rescue group: Vasopressin up to 0.04U/min initiated only if norepinephrine dose exceeds 0.5 μg/kg/min.
Study: NCT06001918
Drug: Nectero EAST System
Normalized name: East Indian lemongrass oil
DrugBank: Lemon (DB10538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.
Study: NCT05275426
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15
Study: NCT04704986
Drug: PVI using the PolarX Cryoballoon (Boston Scientific)
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to PolarX cryoballoon group will undergo PVI using the PolarX Cryoballoon (Boston Scientific).~At the end of the procedure, an implantable cardiac monitor (Medtronic Reveal LINQ) will be implanted for the purpose of continuous arrhythmia monitoring.
Study: NCT05976438
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5mg and Amlodipine 10mg will be one of the study drugs the patients will receive.
Study: NCT05976438
Drug: Chlortalidone
Normalized name: Chlortalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlortalidone 25mg will be one of the study drugs the patients will receive.
Study: NCT06384560
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400 mg will be administered as a 30 minute IV infusion every 6 weeks.
Study: NCT05415722
Drug: TERN-501
Normalized name: TERN-101
DrugBank: TERN-101 (DB16045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT04327310
Drug: Meplazumab for Injection
Normalized name: mepolizumab Injection
DrugBank: Meplazumab (DB16465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: humanized mAb against CD147
Study: NCT04327310
Drug: Sterile normal saline (0.9%)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9%)
Study: NCT05415722
Drug: TERN-101
Normalized name: TERN-101
DrugBank: TERN-101 (DB16045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT06645938
Drug: single dose of vepdegestrant as tablet formulation (Treatment A)
Normalized name: OIL OF CAMPHOR
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.
Study: NCT06645938
Drug: single dose of vepdegestrant as tablet formulation (Treatment B)
Normalized name: OIL OF CAMPHOR
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.
Study: NCT06645704
Drug: EP262
Normalized name: Epoprostenol
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of \[14C\]-EP262 administered orally.
Study: NCT05144984
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
Study: NCT06020495
Drug: DDAVP
Normalized name: DDAVP
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Posology: 4µg in 2ml IV solution Route of administration: Intravenous Duration of treatment: 48h maximum (additional doses every 6h)
Study: NCT04764851
Drug: ecopipam HCl ~2mg/kg/day
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT05794906
Drug: Darolutamide (BAY1841788, Nubeqa)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Coated tablet, 300 mg / tablet, oral.
Study: NCT05970497
Drug: Opdualag
Normalized name: Opdualag
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dual immunotherapy (PD-1 and LAG-3 immune checkpoint inhibitors)
Study: NCT02757534
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
Study: NCT06172010
Drug: Rifampicin and levofloxacin
Normalized name: rifampicin and isoniazid
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Study: NCT05826249
Drug: SIM0417/Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of 750 mg SIM0417 coadministered with 100 mg ritonavir.
Study: NCT05402020
Drug: Tiotropium (Tio)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (Tio)
Study: NCT05402020
Drug: Olodaterol (Olo)
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol (Olo)
Study: NCT04873050
Drug: Semaglutide Pen Injector [Ozempic]
Normalized name: semaglutide Pen Injector [Ozempic]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
Study: NCT04873050
Drug: Placebo semaglutide pen injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
Study: NCT05199727
Drug: Tadalafil 20Mg Oral Tablet
Normalized name: Tadalafil 20mg Oral tablet
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on this arm will allocate on on-demand tadalafil 20 mg for treatment of ED
Study: NCT06646562
Drug: Cabotegravir LA + Rilpivirine LA
Normalized name: rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.
Study: NCT04765722
Drug: Mepolizumab
Normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mepolizumab subcutaneous injection administered 4 times days 0, 28, 56 and 84 during 12 week treatment period.
Study: NCT06645769
Drug: Sodium Phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be compared to placebo
Study: NCT06256627
Drug: recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count.
Study: NCT06429098
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.
Study: NCT06429098
Drug: azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT06429098
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06429098
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05216432
Drug: RLY-2608
Normalized name: RLY-2608
DrugBank: RLY-2608 (DB16751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.
Study: NCT05216432
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg fulvestrant is administered intramuscularly on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (where a cycle is 28 days).
Study: NCT05216432
Drug: Palbociclib 125mg
Normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg palbociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study: NCT05216432
Drug: Ribociclib 400mg
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study: NCT04674176
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
Study: NCT05216432
Drug: Ribociclib 600mg
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600mg ribociclib is taken orally once daily for 28-day cycles that include 21 days of treatment followed by 7 days off treatment.
Study: NCT05216432
Drug: PF-07220060 100mg
Normalized name: cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
Study: NCT05216432
Drug: PF-07220060 300 mg
Normalized name: filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: is taken orally twice daily at the same time with RLY-2608 during each 28-day cycle.
Study: NCT06349837
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive treatment with Tislelizumab (200 mg, iv, d1), every 3 weeks for a maximum of 48 months.
Study: NCT06083948
Drug: Noradrenalin
Normalized name: Noradrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of noradrenaline during anesthesia and surgery
Study: NCT06083948
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion of phenylephrine during anesthesia and surgery
Study: NCT04612699
Drug: Jaktinib
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06318481
Drug: Ticagrelor 90 MG
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the treatment group will receive Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
Study: NCT06318481
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients in the control group will receive Clopidogrel 600 mg as a loading dose and 75 mg twice daily as a maintenance dose for 30 days. After 30-day doses will be according to standards clinical practice guidelines.
Study: NCT06075537
Drug: tividenofusp alfa
Normalized name: Tividenofusp alfa
DrugBank: Tividenofusp alfa (DB17628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT05587712
Drug: Sotatercept
Normalized name: Sotatercept
DrugBank: Sotatercept (DB12118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
Study: NCT05293509
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m2/day i.v.- by vein
Study: NCT05293509
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg/m2/day i.v.-by vein
Study: NCT05287321
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 200mg with Aspirin 100mg
Study: NCT05293509
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
Study: NCT05056337
Drug: Lenvatinib 4 MG Oral Capsule [Lenvima]
Normalized name: lenvatinib 4 MG Oral Capsule [Lenvima]
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
Study: NCT05056337
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)
Study: NCT05293509
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Four doses of rituximab at a dose of 375 mg/m2- by vein
Study: NCT05293509
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 110 mg/m2 i.v-by vein
Study: NCT05293509
Drug: Tacrolimus (or cyclosporine)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: by vein
Study: NCT05293509
Drug: Mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given by PO
Study: NCT04619433
Drug: Camrelizumab;Pemetrexed and Carboplatin; Famitinib;
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part 1:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib~Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Famitinib
Study: NCT04619433
Drug: Camrelizumab;Pemetrexed and Carboplatin;Placebo
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Part 2:~Drug: Camrelizumab; Pemetrexed; Carboplatin; Placebo
Study: NCT04905654
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study: NCT05293509
Drug: Rabbit ATG
Normalized name: Rabbit ATG
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: by vein
Study: NCT05322031
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
Study: NCT04770532
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks
Study: NCT04770532
Drug: Insulin Icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
Study: NCT06351683
Drug: MitoQ (mitoquinol mesylate)
Normalized name: mesylate
DrugBank: Mitoquinone (DB05063)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ is an antioxidant molecule designed to target cell stress
Study: NCT06364423
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
Study: NCT06364423
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/m2 IV infusion over 30 minutes on day -5; 375 mg/m2 IV infusion over 30 minutes on days 2-9 prior to apheresis
Study: NCT06193174
Drug: C134 Re-Administration
Normalized name: Re-Covr
DrugBank: C134 (DB18261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a second dose of C134 to participants that have completed the study Trial of C134 in Patients With Recurrent GBM (C134-HSV-1).
Study: NCT06041568
Drug: Imvotamab
Normalized name: Imvotamab
DrugBank: Imvotamab (DB17331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05265546
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effects of different doses of psilocybin (0 - 14 mg) will be compared.
Study: NCT00004637
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05577468
Drug: Tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tegoprazan-containing bismuth quadruple therapy or Esomeprazole-containing bismuth quadruple therapy; Route of administration: oral;
Study: NCT06139692
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive perioperative sedation with dexmedetomidine
Study: NCT06139692
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive perioperative sedation with midazolam
Study: NCT05295680
Drug: Hymecromone
Normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hymecromone 400 mg 3 times daily by mouth.
Study: NCT05423249
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ferrous sulfate 325 mg once daily, containing 65 mg of elemental iron to treat non-anemic iron deficiency
Study: NCT05423249
Drug: Prenatal
Normalized name: Prenatal
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prenatal vitamin once daily for both groups
Study: NCT05423249
Drug: Docusate Sodium
Normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral docusate sodium 100 mg twice daily as needed, to treat constipation secondary to oral iron supplementation
Study: NCT04414514
Drug: Ruxolitinib 1.5% Cream
Normalized name: RUXOLITINIB 1.5% CREAM,TOP
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Ruxolitinib 1.5% Cream
Study: NCT04847622
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treated with Remdesivir
Study: NCT06455462
Drug: Tezepelumab
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tezepelumab treatment initiated as part of the tezepelumab patient access programme (TPAP) between 1st January 2023 and 19th July 2023
Study: NCT06388187
Drug: Cagrilintide
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once-weekly cagrilintide subcutaneously.
Study: NCT06388187
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive once-weekly semaglutide subcutaneously.
Study: NCT04950075
Drug: INBRX-109
Normalized name: INBRX-101
DrugBank: INBRX-101 (DB18384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent DR5 Agonist Antibody
Study: NCT05078710
Drug: Telitacicept
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160mg once a week for 24 weeks
Study: NCT05114421
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04745637
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive Ruxolitinib
Study: NCT04805944
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
Study: NCT04805944
Drug: Bictegravir
Normalized name: Bictegravir
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
Study: NCT03123211
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib will be administered orally.